Additionally, we discuss recent preclinical and clinical studies to explore VEGF/VEGFR-targeted compounds and immunotherapy as novel approaches targeting the TME for the treatment of NSCLC. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.